BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biospring Selects GE Healthcare Life Sciences Oligoprocess™ For Large Scale Synthesis Of Therapeutic Oligonucleotides


5/13/2014 8:51:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHALFONT ST. GILES, UK and FRANKFURT, GERMANY – 13 May 2014 – GE Healthcare Life Sciences (NYSE: GE) and German oligonucleotide manufacturer BioSpring GmbH announced today that BioSpring has selected and installed GE Healthcare Life Sciences’ OligoProcess, a fully automated oligonucleotide synthesizer, as a core element of its state-of-the-art production facility in Frankfurt.

Oligonucleotides are short sequences of DNA or RNA which can modify the expression of genes involved in disease pathways, leading to considerable interest in their potential as next-generation therapeutic agents for treating a wide variety of diseases such as cancer, asthma and diabetes. GE Healthcare’s OligoProcess is a customizable platform for the synthesis of therapeutic oligonucleotides, designed to allow manufacturing scale-up from early stage clinical research to post-marketing manufacture on the same system. This single system approach greatly simplifies manufacturing process development, offering the potential to save both time and money as well as reduce project risk.

Dr. Sylvia Wojczewski, CEO of BioSpring, said: “We are very excited to be the first in the world to have this new technology platform in our facility because it will enable us to improve the output and flexibility of our manufacturing capabilities. The ability to go from pilot scale to full manufacturing scale on the same system, which OligoProcess delivers, is a key requirement for us in serving our customers more effectively and efficiently than before.”

Emmanuel Ligner, Global Commercial Manager, BioProcess, GE Healthcare Life Sciences, said: “We are seeing a real diversification in the types of molecules that the industry is developing for therapeutic use, to include fragment antibodies, antibody-drug conjugates, vaccines and oligonucleotides. Our driver is to develop the technologies, tools and services which help the industry to manufacture a quality product in the most cost-effective way possible. With the help of our technology, BioSpring has enhanced its offering to companies needing manufacturing-scale production of oligonucleotides for therapeutic use.”

GE Healthcare offers a wide range of start-to-finish technologies and services for the discovery and manufacture of innovative new medicines and vaccines. In March 2014 the company acquired Thermo Fisher’s HyClone™ cell culture media and sera business and in 2012 the company launched KUBio™, an off-the-shelf modular factory for the manufacture of monoclonal antibodies. BioSpring has a number of collaborations with leading pharmaceutical companies. On Wednesday 14th May 2014, GE Healthcare and BioSpring will present data on the OligoProcess oligonucleotide manufacturing system at the 16th Annual TIDES Conference, Providence, RI, USA.

About BioSpring
BioSpring is a cGMP and ISO 13485 certified specialist manufacturer of therapeutic, diagnostic and research oligonucleotides and a provider of analytical services related to oligonucleotides. BioSpring accompanies projects in the oligonucleotide field from early research to the marketing phase employing efficient manufacturing and analytical technologies. Hereby BioSpring supports its customers worldwide to efficiently develop their oligonucleotide products. BioSpring is a privately owned company with headquarters in Frankfurt, Germany, that has been providing services to the oligonucleotide industry for more than 17 years. For more information about BioSpring, please visit www.biospring.de.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

Issued for and on behalf of GE Healthcare by Instinctif Partners.

Contact:
GE Healthcare
Dr. Val Jones, Global Media Relations Manager
T +44 7917 175 192
E val.jones@ge.com
@GEHealthcare
BioSpring GmbH
USA - Dr. Jeremy Little
T +1.781.315.5514
E little@biospring.de
www.biospring-usa.com
Europe - Frederika Debusschere
T +49 69 4080 7222
E debusschere@biospring.de
www.biospring.de

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->